Wiener medizinische Wochenschrift (1946) · 2024
Significance of plasma relaxin-2 levels in patients with primary hypertension and type 2 diabetes mellitus.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Pankova Olena, Korzh Oleksii
Аннотация
BACKGROUND: This study aimed to evaluate plasma relaxin‑2 (RLN-2) levels in patients with arterial hypertension (AH) and their relationships with clinical and laboratory parameters.
METHODS: The study involved 106 hypertensive patients, including 55 with type 2 diabetes mellitus (T2DM), and 30 control subjects. Plasma RLN-2 levels were measured using an enzyme-linked immunosorbent assay kit.
RESULTS: RLN-2 levels were reduced in patients with AH compared to healthy volunteers (p < 0.001), and hypertensive patients with T2DM had lower RLN-2 levels than those without impaired glucose metabolism (p < 0.001). RLN‑2 was negatively correlated with systolic blood pressure (SBP) (p < 0.001) and anthropometric parameters such as body mass index (BMI; p = 0.027), neck (p = 0.045) and waist (p = 0.003) circumferences, and waist-to-hip ratio (p = 0.011). RLN‑2 also had inverse associations with uric acid levels (p = 0.019) and lipid profile parameters, particularly triglycerides (p < 0.001) and non-HDL-C/HDL‑C (p < 0.001), and a positive relationship with HDL‑C (p < 0.001). RLN‑2 was negatively associated with glucose (p < 0.001), insulin (p = 0.043), HbA1c (p < 0.001), and HOMA-IR index (p < 0.001). Univariate binary logistic regression identified RLN‑2 as a significant predictor of impaired glucose metabolism (p < 0.001).
CONCLUSIONS: Decreased RLN-2 levels in patients with AH and T2DM and established relationships of RLN‑2 with SBP and parameters of glucose metabolism and lipid profile suggest a diagnostic role of RLN‑2 as a biomarker for AH with T2DM.
METHODS: The study involved 106 hypertensive patients, including 55 with type 2 diabetes mellitus (T2DM), and 30 control subjects. Plasma RLN-2 levels were measured using an enzyme-linked immunosorbent assay kit.
RESULTS: RLN-2 levels were reduced in patients with AH compared to healthy volunteers (p < 0.001), and hypertensive patients with T2DM had lower RLN-2 levels than those without impaired glucose metabolism (p < 0.001). RLN‑2 was negatively correlated with systolic blood pressure (SBP) (p < 0.001) and anthropometric parameters such as body mass index (BMI; p = 0.027), neck (p = 0.045) and waist (p = 0.003) circumferences, and waist-to-hip ratio (p = 0.011). RLN‑2 also had inverse associations with uric acid levels (p = 0.019) and lipid profile parameters, particularly triglycerides (p < 0.001) and non-HDL-C/HDL‑C (p < 0.001), and a positive relationship with HDL‑C (p < 0.001). RLN‑2 was negatively associated with glucose (p < 0.001), insulin (p = 0.043), HbA1c (p < 0.001), and HOMA-IR index (p < 0.001). Univariate binary logistic regression identified RLN‑2 as a significant predictor of impaired glucose metabolism (p < 0.001).
CONCLUSIONS: Decreased RLN-2 levels in patients with AH and T2DM and established relationships of RLN‑2 with SBP and parameters of glucose metabolism and lipid profile suggest a diagnostic role of RLN‑2 as a biomarker for AH with T2DM.